share_log

Sera Prognostics | 10-Q: Q3 2024 Earnings Report

Sera Prognostics | 10-Q: Q3 2024 Earnings Report

Sera Prognostics | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/07 11:32

Moomoo AI 已提取核心信息

Sera Prognostics reported Q3 2024 financial results with revenue of $29,000 and a net loss of $7.9 million, compared to $42,000 revenue and $7.2 million net loss in Q3 2023. The company ended the quarter with $74.3 million in cash, cash equivalents and marketable securities, which is expected to fund operations into 2027.The company made significant progress with its PreTRM test, announcing positive results from the AVERT PRETERM TRIAL showing an 18% reduction in severe neonatal morbidity and mortality. The PRIME study enrollment was stopped in December 2023 due to efficacy, with final database lock completed in September 2024. Top-level trial results were communicated in October 2024.Sera continues to focus on market adoption of PreTRM test through evidence generation and commercial strategy refinement. The company established a new at-the-market offering program for up to $50 million and implemented whole-blood specimen collection to enable greater market penetration. Operating expenses were $8.9 million for Q3 2024, compared to $8.2 million in Q3 2023.
Sera Prognostics reported Q3 2024 financial results with revenue of $29,000 and a net loss of $7.9 million, compared to $42,000 revenue and $7.2 million net loss in Q3 2023. The company ended the quarter with $74.3 million in cash, cash equivalents and marketable securities, which is expected to fund operations into 2027.The company made significant progress with its PreTRM test, announcing positive results from the AVERT PRETERM TRIAL showing an 18% reduction in severe neonatal morbidity and mortality. The PRIME study enrollment was stopped in December 2023 due to efficacy, with final database lock completed in September 2024. Top-level trial results were communicated in October 2024.Sera continues to focus on market adoption of PreTRM test through evidence generation and commercial strategy refinement. The company established a new at-the-market offering program for up to $50 million and implemented whole-blood specimen collection to enable greater market penetration. Operating expenses were $8.9 million for Q3 2024, compared to $8.2 million in Q3 2023.
Sera Prognostics公布了2024年第三季度财务结果，营业收入为29,000美元，净亏损为790万元，而2023年第三季度的营业收入为42,000美元，净亏损为720万元。公司结束该季度时现金、现金等价物及可交易证券为7430万元，预计这将支持其运营直到2027年。公司在PreTRm测试上取得了显著进展，宣布了来自AVERt PRETERm TRIAL的积极结果，显示严重新生儿发病率和死亡率降低了18%。由于疗效，PRIME研究的招募于2023年12月停止，最终数据库锁定于2024年9月完成。顶级试验结果于2024年10月公布。Sera继续专注于通过证据生成和商业策略优化，推动PreTRm测试的市场接受度。公司建立了一项新的市场发行计划，最高额度为5000万元，并实施了全血样本收集，以促进更大的市场渗透。2024年第三季度的营业费用为890万元，而2023年第三季度为820万元。
Sera Prognostics公布了2024年第三季度财务结果，营业收入为29,000美元，净亏损为790万元，而2023年第三季度的营业收入为42,000美元，净亏损为720万元。公司结束该季度时现金、现金等价物及可交易证券为7430万元，预计这将支持其运营直到2027年。公司在PreTRm测试上取得了显著进展，宣布了来自AVERt PRETERm TRIAL的积极结果，显示严重新生儿发病率和死亡率降低了18%。由于疗效，PRIME研究的招募于2023年12月停止，最终数据库锁定于2024年9月完成。顶级试验结果于2024年10月公布。Sera继续专注于通过证据生成和商业策略优化，推动PreTRm测试的市场接受度。公司建立了一项新的市场发行计划，最高额度为5000万元，并实施了全血样本收集，以促进更大的市场渗透。2024年第三季度的营业费用为890万元，而2023年第三季度为820万元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    飞天兆业
    PTHL
    -- 3.185
    古特拉
    CUTR
    -- 0.129
    908 Devices
    MASS
    -- 3.020
    Elutia
    ELUT
    -- 3.000
    Catheter Precision
    VTAK
    -- 0.336
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    两会召开：中概股走势将如何演变？
    🎙️讨论 1. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 2. 你预计“两会”期间出台的政策将如何影响你的投资策略？ 3. 你对“两会”期间股市的波动性有何预期？ 展开
    中国两会：会议前后股票价格走势的主要要点